Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1230-1235

  Yuan, Lili ^a,b   Wang, Ying ^c   Parker, Daniel M ^b   Gupta, Bhavna ^b   Yang, Zhaoqing ^a   Liu, Huaie ^a   Fan, Qi ^d   Cao, Yaming ^e   Xiao, Yuping ^e   Lee, Ming Chieh ^f   Zhou, Guofa ^f   Yan, Guiyun ^f   Baird, J Kevin ^g,h   Cui, Liwang ^b  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c THIRD MILITARY MEDICAL UNIVERSITY   (China)

^d Dalian Institute of Biotechnology   (China)

^e CHINA MEDICAL UNIVERSITY   (China)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; PRIMAQUINE; ANTIMALARIAL AGENT;

ADOLESCENT; ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; BLOODSTREAM INFECTION; CHILD; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE LOCUS; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEROZOITE; MYANMAR; PARASITEMIA; PLASMODIUM VIVAX MALARIA; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT RESPONSE; DRUG EFFECTS; INFANT; MALARIA, VIVAX; MIDDLE AGED; PATHOGENICITY; PLASMODIUM VIVAX; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; FEMALE; GENOTYPE; HUMANS; INFANT; MALARIA, VIVAX; MALE; MIDDLE AGED; PLASMODIUM VIVAX; PRIMAQUINE; YOUNG ADULT;

EID: 84921912428     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04270-14     Document Type: Article

References (45)

1. Gething PW, Elyazar IR, Moyes CL, Smith DL, Battle KE, Guerra CA, Patil AP, Tatem AJ, Howes RE, Myers MF, George DB, Horby P, Wertheim HF, Price RN, Mueller I, Baird JK, Hay SI. 2012. A long neglected world malaria map: Plasmodium vivax endemicity in 2010.PLoS Negl Trop Dis 6:e1814. http://dx.doi.org/10.1371/journal.pntd .0001814.
2. Hay SI, Guerra CA, Tatem AJ, Noor AM, Snow RW. 2004. The global distribution and population at risk of malaria: past, present, and future. Lancet Infect Dis 4:327-336. http://dx.doi.org/10.1016/S1473-3099(04)01043-6.
3. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. 2007. Vivax malaria: neglected and not benign. Am J Trop Med Hyg 77(6 Suppl):79-87.
4. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RG. 2013. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382:900-911. http://dx.doi.org/10.1016/S0140-6736(13)60310-4.
5. Feachem RG, Phillips AA, Hwang J, Cotter C, Wielgosz B, Greenwood BM, Sabot O, Rodriguez MH, Abeyasinghe RR, Ghebreyesus TA, Snow RW. 2010. Shrinking the malaria map: progress and prospects. Lancet 376:1566-1578. http://dx.doi.org/10.1016/S0140-6736(10)61270-6.
6. Baird JK. 2009. Resistance to therapies for infection by Plasmodium vivax. Clin Microbiol Rev 22:508-534. http://dx.doi.org/10.1128/CMR .00008-09.
7. Baird JK. 2011. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother 55:1827-1830. http://dx.doi.org /10.1128/AAC.01296-10.
8. Rieckmann KH, Davis DR, Hutton DC. 1989. Plasmodium vivax resistance to chloroquine? Lancet ii:1183-1184.
9. Schuurkamp GJ, Spicer PE, Kereu RK, Bulungol PK, Rieckmann KH.1992. Chloroquine-resistant Plasmodium vivax in Papua New Guinea. Trans R Soc Trop Med Hyg 86:121-122. http://dx.doi.org/10.1016/0035 -9203(92)90531-G.
10. Baird JK, Basri H, Purnomo Bangs MJ, Subianto B, Patchen LC, Hoffman SL. 1991. Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am J Trop Med Hyg 44:547-552.
11. Collignon P. 1991. Chloroquine resistance in Plasmodium vivax. J Infect Dis 164:222-223. http://dx.doi.org/10.1093/infdis/164.1.222.
12. Schwartz IK, Lackritz EM, Patchen LC. 1991. Chloroquine-resistant Plasmodium vivax from Indonesia. N Engl J Med 324:927. http://dx.doi .org/10.1056/NEJM199103283241317.
13. Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ.2014. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis 14:982-991. http://dx.doi .org/10.1016/S1473-3099(14)70855-2.
14. Price RN, Auburn S, Marfurt J, Cheng Q. 2012. Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends Parasitol 28:522-529. http://dx.doi.org/10.1016/j.pt.2012.08.005.
15. Cui L, Yan G, Sattabongkot J, Cao Y, Chen B, Chen X, Fan Q, Fang Q, Jongwutiwes S, Parker D, Sirichaisinthop J, Kyaw MP, Su XZ, Yang H, Yang Z, Wang B, Xu J, Zheng B, Zhong D, Zhou G. 2012. Malaria in the Greater Mekong Subregion: heterogeneity and complexity. Acta Trop 121: 227-239. http://dx.doi.org/10.1016/j.actatropica.2011.02.016.
16. Delacollette C, D'Souza C, Christophel E, Thimasarn K, Abdur R, Bell D, Dai TC, Gopinath D, Lu S, Mendoza R, Ortega L, Rastogi R, Tantinimitkul C, Ehrenberg J. 2009. Malaria trends and challenges in the Greater Mekong Subregion. Southeast Asian J Trop Med Public Health 40:674-691.
17. Myat-Phone-Kyawm, Myint-Oo, Myint-Lwin, Thaw-Zin, Kyin-Hla- Aye, Nwe-Nwe-Yin. 1993. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma). Trans R Soc Trop Med Hyg 87:687.http://dx.doi.org/10.1016/0035-9203(93)90294-Z.
18. Marlar-Than, Myat-Phone-Kyaw, Aye-Yu-Soe, Khaing-Khaing-Gyi, Ma-Sabai, Myint-Oo. 1995. Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans R Soc Trop Med Hyg 89:307-308.http://dx.doi.org/10.1016/0035-9203(95)90556-1.
19. Guthmann JP, Pittet A, Lesage A, Imwong M, Lindegardh N, Min Lwin M, Zaw T, Annerberg A, de Radigues X, Nosten F. 2008. Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar. TropMedInt Health 13:91-98. http://dx.doi.org/10.1111/j.1365-3156.2007.01978.x.
20. Li N, Parker DM, Yang Z, Fan Q, Zhou G, Ai G, Duan J, Lee MC, Yan G, Matthews SA, Cui L, Wang Y. 2013. Risk factors associated with slidepositivity among febrile patients in a conflict zone of north-eastern Myanmar along the China-Myanmar border. Malar J 12:361. http://dx.doi.org /10.1186/1475-2875-12-361.
21. Bruce MC, Galinski MR, Barnwell JW, Snounou G, Day KP. 1999.Polymorphism at the merozoite surface protein-3- locus of Plasmodium vivax: global and local diversity. Am J Trop Med Hyg 61:518-525.
22. Cui L, Mascorro CN, Fan Q, Rzomp KA, Khuntirat B, Zhou G, Chen H, Yan G, Sattabongkot J. 2003. Genetic diversity and multiple infections of Plasmodium vivax malaria in western Thailand. Am J Trop Med Hyg 68:613-619.
23. Baird JK, Wiady I, Fryauff DJ, Sutanihardja MA, Leksana B, Widjaya H, Kysdarmanto Subianto B. 1997. In vivo resistance to chloroquine by Plasmodium vivax and Plasmodium falciparum at Nabire, Irian Jaya, Indonesia. Am J Trop Med Hyg 56:627-631.
24. Pukrittayakamee S, Imwong M, Chotivanich K, Singhasivanon P, Day NP, White NJ. 2010. A comparison of two short-course primaquine regimens for the treatment and radical cure of Plasmodium vivax malaria in Thailand. Am J Trop Med Hyg 82:542-547. http://dx.doi.org/10.4269 /ajtmh.2010.09-0428.
25. Pukrittayakamee S, Vanijanonta S, Chantra A, Clemens R, White NJ.1994. Blood stage antimalarial efficacy of primaquine in Plasmodium vivax malaria. J Infect Dis 169:932-935. http://dx.doi.org/10.1093/infdis /169.4.932.
26. Bray PG, Deed S, Fox E, Kalkanidis M, Mungthin M, Deady LW, Tilley L. 2005. Primaquine synergises the activity of chloroquine against chloro-quine- resistant P. falciparum. Biochem Pharmacol 70:1158-1166. http: //dx.doi.org/10.1016/j.bcp.2005.07.021.
27. Baird JK, Wiady I, Sutanihardja A, Suradi Purnomo Basri H, Sekartuti Ayomi E, Fryauff DJ, Hoffman SL. 2002. Short report: therapeutic efficacy of chloroquine combined with primaquine against Plasmodium falciparum in northeastern Papua, Indonesia. Am J Trop Med Hyg 66: 659-660.
28. Baird JK, Basri H, Subianto B, Fryauff DJ, McElroy PD, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL. 1995. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 171:1678-1682. http://dx.doi.org/10 .1093/infdis/171.6.1678.
29. Luxemburger C, van Vugt M, Jonathan S, McGready R, Looareesuwan S, White NJ, Nosten F. 1999. Treatment of vivax malaria on the western border of Thailand. Trans R Soc Trop Med Hyg 93:433-438. http://dx.doi .org/10.1016/S0035-9203(99)90149-9.
30. Pukrittayakamee S, Chantra A, Simpson JA, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. 2000. Therapeutic responses to different antimalarial drugs in vivax malaria. Antimicrob Agents Chemother 44: 1680-1685. http://dx.doi.org/10.1128/AAC.44.6.1680-1685.2000.
31. Tasanor O, Ruengweerayut R, Sirichaisinthop J, Congpuong K, Wernsdorfer WH, Na-Bangchang K. 2006. Clinical-parasitological response and in-vitro sensitivity of Plasmodium vivax to chloroquine and quinine on the western border of Thailand. Trans R Soc Trop Med Hyg 100:410-418. http://dx.doi.org/10.1016/j.trstmh.2005.04.024.
32. Muhamad P, Ruengweerayut R, Chacharoenkul W, Rungsihirunrat K, Na-Bangchang K. 2011. Monitoring of clinical efficacy and in vitro sensitivity of Plasmodium vivax to chloroquine in area along Thai Myanmar border during 2009-2010. Malar J 10:44. http://dx.doi.org/10.1186/1475 -2875-10-44.
33. Vijaykadga S, Rojanawatsirivej C, Congpoung K, Wilairatana P, SatimaiW, Uaekowitchai C, Pumborplub B, Sittimongkol S, Pinyorattanachote A, Prigchoo P. 2004. Assessment of therapeutic efficacy of chloroquine for vivax malaria in Thailand. Southeast Asian J Trop Med Public Health 35:566-569.
34. Congpoung K, Satimai W, Sujariyakul A, Intanakom S, Harnpitakpong W, Pranuth Y, Cholpol S, Bualombai P. 2011. In vivo sensitivity monitoring of chloroquine for the treatment of uncomplicated vivax malaria in four bordered provinces of Thailand during 2009-2010. J Vector Borne Dis 48:190-196.
35. Liu H, Yang HL, Tang LH, Li XL, Huang F, Wang JZ, Li CF, Wang HY, Nie RH, Guo XR, Lin YX, Li M, Xu JW. 2014. Monitoring Plasmodium vivax chloroquine sensitivity along China-Myanmar border of Yunnan Province, China during 2008-2013. Malar J 13:364. http://dx.doi.org/10 .1186/1475-2875-13-364.
36. Phyo AP, Lwin KM, Price RN, Ashley EA, Russell B, Sriprawat K, Lindegardh N, Singhasivanon P, White NJ, Nosten F. 2011. Dihydro-artemisinin- piperaquine versus chloroquine in the treatment of Plasmodium vivax malaria in Thailand: a randomized controlled trial. Clin Infect Dis 53:977-984. http://dx.doi.org/10.1093/cid/cir631.
37. Rijken MJ, Boel ME, Russell B, Imwong M, Leimanis ML, Phyo AP, Muehlenbachs A, Lindegardh N, McGready R, Renia L, Snounou G, Singhasivanon P, Nosten F. 2011. Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malar J 10:113.http://dx.doi.org/10.1186/1475-2875-10-113.
38. Liang GL, Sun XD, Wang J, Zhang ZX. 2009. Sensitivity of Plasmodium vivax to chloroquine in Laza City, Myanmar. Chin J Parasitol Parasitic Dis 27:175-176. (In Chinese.)
39. Murphy GS, Basri H, Purnomo Andersen EM, Bangs MJ, Mount DL, Gorden J, Lal AA, Purwokusumo AR, Harjosuwarno S, et al. 1993.Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet 341:96-100. http://dx.doi.org/10.1016/0140-6736(93)92568-E.
40. Ruebush TK, II, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, Marquino W, Huilca M, Arevalo E, Garcia C, Solary L, Kain KC. 2003.Chloroquine-resistant Plasmodium vivax malaria in Peru.AmJ Trop Med Hyg 69:548-552.
41. Graf PC, Durand S, Alvarez Antonio C, Montalvan C, Galves Montoya M, Green MD, Santolalla ML, Salas C, Lucas C, Bacon DJ, Fryauff DJ.2012. Failure of supervised chloroquine and primaquine regimen for the treatment of Plasmodium vivax in the Peruvian Amazon. Malar Res Treat 2012:936067. http://dx.doi.org/10.1155/2012/936067.
42. Pukrittayakamee S, Imwong M, Singhasivanon P, Stepniewska K, Day NJ, White NJ. 2008. Effects of different antimalarial drugs on gametocyte carriage in P. vivax malaria. Am J Trop Med Hyg 79:378-384.
43. Douglas NM, Simpson JA, Phyo AP, Siswantoro H, Hasugian AR, Kenangalem E, Poespoprodjo JR, Singhasivanon P, Anstey NM, White NJ, Tjitra E, Nosten F, Price RN. 2013. Gametocyte dynamics and the role of drugs in reducing the transmission potential of Plasmodium vivax. J Infect Dis 208:801-812. http://dx.doi.org/10.1093/infdis/jit261.
44. Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, Guthmann JP, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day NP, Anderson TJ, White NJ. 2007. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195:927-933. http://dx.doi.org/10.1086/512241.
45. Douglas NM, Anstey NM, Angus BJ, Nosten F, Price RN. 2010. Artemisinin combination therapy for vivax malaria. Lancet Infect Dis 10:405-416. http://dx.doi.org/10.1016/S1473-3099(10)70079-7.